Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pegvisomant-induced liver injury is related to the UGT1A1*28 polymorphism of Gilbert's syndrome.

The Journal of clinical endocrinology and metabolism - 1 May 2010

Bernabeu Ignacio, Marazuela Mónica, Lucas Tomás, Loidi Lourdes, Alvarez-Escolá Cristina, Luque-Ramírez Manuel, Fernandez-Rodriguez Eva, Paniagua Amalia-Elisa, Quinteiro Celsa, Casanueva Felipe F

Abstract excerpt

CONTEXT: Pegvisomant (PEG) therapy has been associated with drug-induced liver dysfunction in acromegalic patients. The mechanism of its toxicity remains unknown. OBJECTIVE: The primary objective was to determine whether or not the UGT1A1*28 polymorphism associated with Gilbert's syndrome influen...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acromegaly
Share to Alcohol Drinking

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gilbert Disease

Share to Glucuronosyltransferase

Share to Human Growth Hormone

Share to Liver Diseases

Share to Receptors, Somatotropin

Share to TATA Box

Source

Identifiers

PMID: 20207827
DOI: 10.1210/jc.2009-2547

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20207827-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pegvisomant-induced liver injury is related to the UGT1A1*28 polymorphism of Gilbert's syndrome.PMID 20207827Read ↗

Role of UGT1A1 and ADH gene polymorphisms in pegvisomant-induced liver toxicity in acromegalic patients.Semantic proximity Read ↗

Genetic Predictors of Response to Different Medical Therapies in Acromegaly.Semantic proximity Read ↗

Gilbert-Meulengracht's syndrome and pharmacogenetics: is jaundice just the tip of the iceberg?Semantic proximity Read ↗

Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study.Semantic proximity Read ↗

Drug-induced acute cholestatic liver damage in a patient with mutation of UGT1A1.Semantic proximity Read ↗

[Gilbert's syndrome: a clinicogenetic trial].Semantic proximity Read ↗

The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly.Semantic proximity Read ↗

Is there any association between the Ser326Cys polymorphism of the 8-oxoguanine glycosylase 1 (OGG1) gene and risk of colon polyp and abnormal glucose tolerance in acromegaly patients?Semantic proximity Read ↗

Treatment of acromegaly in the era of personalized and predictive medicine.Semantic proximity Read ↗

FEATURES OF GILBERT'S SYNDROME IN PATIENTS WITH DIFFERENT GENOTYPES UGT1AI.Semantic proximity Read ↗

Role of UDP-Glucuronosyltransferase 1A1 in the Metabolism and Pharmacokinetics of Silymarin Flavonolignans in Patients with HCV and NAFLD.Semantic proximity Read ↗

GSTP1 gene methylation and AHR rs2066853 variant predict resistance to first generation somatostatin analogs in patients with acromegalySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.